The Valve Industry's Quantum Leap Forward The Centers for Medicare & Medicaid Services (CMS) recent update to its National Coverage Determination (NCD) for Transcatheter Aortic Valve Replacement (TAVR) has sent shockwaves through the structural heart disease market.
Edwards Lifesciences, a leading player in this field, sees the decision as a major catalyst for growth.
The updated policy provides greater flexibility for patient evaluations and procedure staffing, allowing up to 200 additional centers to offer TAVR over time.